Helsinn to acquire global rights of Valchlor/Ledaga from Actelion Pharmaceuticals
Completion of the acquisition is subject to customary closing conditions, and is expected to close in the second quarter of 2018. Valchlor® is the first and only FDA-approved
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.